Cdnf Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
--- [1]
title: CDNF Gene [2]
description: CDNF is a neurotrophic factor that protects dopaminergic neurons. [3]
--- [4]
| CDNF Gene | |
|---|---|
| Cerebral Dopamine Neurotrophic Factor | |
| Gene Symbol | CDNF |
| Full Name | Cerebral Dopamine Neurotrophic Factor |
| Chromosomal Location | 10p13 |
| NCBI Gene ID | [124403](https://www.ncbi.nlm.nih.gov/gene/124403) |
| OMIM | [611088](https://www.omim.org/entry/611088) |
| Ensembl ID | [ENSG00000154917](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000154917) |
| UniProt ID | [Q96GS4](https://www.uniprot.org/uniprot/Q96GS4) |
| Protein Family | MANF/CDNF family |
| Associated Diseases | Parkinson's Disease, Dopaminergic Neurodegeneration |
CDNF (Cerebral Dopamine Neurotrophic Factor) is a secreted neurotrophic protein that promotes the survival, function, and regeneration of dopaminergic neurons. Discovered in 2007, CDNF belongs to the MANF/CDNF family of neurotrophic factors, which are structurally and functionally distinct from the GDNF family. CDNF has emerged as a promising disease-modifying therapy for Parkinson's disease due to its unique mechanism of action and neuroprotective properties.
CDNF is a secreted protein with a distinctive bipartite structure:
N-terminal domain (1-60 aa): Contains an ER retention signal sequence (RSNL) that directs protein to the endoplasmic reticulum. This region is involved in protein-protein interactions and ER homeostasis.
C-terminal domain (61-182 aa): The secreted portion contains the neurotrophic activity and mediates receptor interactions on target neurons.
The protein is highly conserved across mammals and is expressed primarily in the central nervous system, with particularly high expression in dopaminergic regions including the substantia nigra and striatum.
CDNF performs several critical functions in the nervous system:
CDNF promotes the survival and maintenance of dopaminergic neurons through activation of intracellular signaling cascades. It supports neuronal morphology, axonal growth, and synaptic function.
Unlike most neurotrophic factors, CDNF localizes to the endoplasmic reticulum where it participates in protein quality control and ER homeostasis. This function is particularly important under conditions of cellular stress.
CDNF helps maintain proteostasis by assisting in the folding and trafficking of proteins, reducing the accumulation of misfolded proteins that contribute to neurodegeneration.
CDNF exerts its neuroprotective effects through multiple mechanisms:
CDNF binds to a still-characterized receptor on dopaminergic neurons, activating downstream signaling pathways including:
The ER-localized fraction of CDNF provides direct protection against ER stress, which is particularly relevant in Parkinson's disease where protein misfolding and ER stress are major pathological features.
CDNF is primarily investigated for its potential in Parkinson's disease therapy:
CDNF represents a promising disease-modifying therapy for Parkinson's disease:
Potential biomarkers for CDNF therapy include:
CDNF's unique ER localization provides direct protection against ER stress, a key pathological feature in Parkinson's disease:
CDNF enhances autophagy, a critical cellular clearance mechanism impaired in neurodegenerative diseases:
CDNF modulates neuroinflammation through several mechanisms:
CDNF contains two functionally distinct domains:
| Domain | Amino Acids | Function |
|---|---|---|
| N-terminal | 1-60 | ER retention; protein interactions |
| C-terminal | 61-182 | Neurotrophic activity; receptor binding |
The C-terminal domain adopts a fold distinct from other neurotrophic factors:
CDNF undergoes several modifications:
CDNF has demonstrated efficacy in multiple preclinical models:
| Model | Route | Outcome | Reference |
|---|---|---|---|
| 6-OHDA rat | Intracerebral | 80% DA neuron rescue | PMID:17656442 |
| MPTP mouse | Intranasal | Protected DA neurons | PMID:21882242 |
| α-Syn preformed fibrils | AAV-CDNF | Reduced pathology | PMID:33486734 |
| Aged mice | Systemic | Improved motor function | PMID:30235908 |
CDNF has reached early-stage clinical development:
Multiple delivery approaches are being evaluated:
CDNF distribution characteristics:
CDNF has shown favorable safety in preclinical models:
| Property | CDNF | GDNF |
|---|---|---|
| Receptor | Partially characterized | GFRα1/RET |
| Delivery | Multiple routes | Requires direct injection |
| ER localization | Yes | No |
| Safety profile | Favorable | Requires careful monitoring |
| Clinical stage | Early | Advanced |
CDNF and MANF (Armet) are structurally and functionally related:
The study of Cdnf Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Voutilainen et al. CDNF: A novel neurotrophic factor for Parkinson's disease (2009). 2009. ↩︎
Airavaara et al. CDNF gene therapy for Parkinson's disease (2012). 2012. ↩︎
Chen et al. CDNF protein delivery reduces alpha-synuclein pathology (2021). 2021. ↩︎
Decressac et al. CDNF neuroprotection in vivo (2011). 2011. ↩︎